Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty.

Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance reforms, the return of funds to the Company, and a court-approved incentive award, all at no cost to them.

What Should REGENXBIO Shareholders Do?

If you have held REGENXBIO shares continuously since prior to February 9, 2022, you may have standing to seek corporate governance reforms at REGENXBIO, including improvements to internal controls, transparency, and executive oversight.

To learn more, visit: https://www.johnsonfistel.com/investigations/regenxbio/

You may also contact Johnson Fistel, PLLP at [e-mail] or [phone]. There is no cost or obligation to you.

Complaint Allegations

A previously filed federal securities class action complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:

1. REGENXBIO’s positive statements concerning the anticipated success of RGX-111’s Phase I/II clinical trial emphasized favorable biomarker, safety, and neurodevelopmental data while allegedly omitting material safety concerns;
2. Defendants allegedly concealed or minimized serious safety risks associated with the RGX-111 study, including the potential for a central nervous system neoplasm; and
3. As a result, defendants’ statements concerning REGENXBIO’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The complaint further alleges that, on January 28, 2026, REGENXBIO announced that the FDA had placed RGX-111 on clinical hold after an intraventricular central nervous system tumor was identified in a participant treated in the RGX-111 Phase I/II study. REGENXBIO’s stock price fell from $13.41 per share on January 27, 2026, to $11.01 per share on January 28, 2026, a decline of approximately 17.8%.

About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. The firm also represents foreign investors who have purchased securities on U.S. exchanges.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.